by EmpathiCSubstanceS | Aug 11, 2022 | Psychedelic Research
Psilocybin’s acute psychedelic effects typically became detectable 30-60 min after dosing, peaked 2-3 h after dosing, and subsided to negligible levels at least 6 h after dosing. Mean self-rated intensity (on a 0-1 scale) was 0·51 (SD 0·36) for the low-dose...
by EmpathiCSubstanceS | Aug 11, 2022 | Psychedelic Research
In MDMA studies, participants report improved self‐knowledge, sleep regulation, accuracy in perceiving mental states of others, coping strategies, emotion regulation, and cognitive insights. Objective measures support attenuated impact of social rejection and reduced...
by EmpathiCSubstanceS | Aug 11, 2022 | Psychedelic Research
Of those reporting a history of being diagnosed with depression (n=149; 41%) or anxiety (n=173; 48%), most reported symptoms were improved (depression=81%; anxiety=79%) following 5-MeO-DMT use and relatively fewer reported symptoms remained the same (depression=17%;...
by EmpathiCSubstanceS | Aug 11, 2022 | Psychedelic Research
Of those reporting having been diagnosed with depression (41%) or anxiety (48%), most reported these conditions were improved (depression=80%; anxiety=79%) following 5-MeO-DMT use, and fewer reported they were unchanged (depression=17%; anxiety=19%) or worsened...
by EmpathiCSubstanceS | Aug 11, 2022 | Psychedelic Research
At the 2-month follow-up, positive trends were found via the State-Trait Anxiety Inventory (STAI) in reductions in trait anxiety (p = 0.033) with an effect size of 1.1, and state anxiety was significantly reduced (p = 0.021) with an effect size of 1.2, with no acute...
by EmpathiCSubstanceS | Aug 11, 2022 | Psychedelic Research
High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety. At 6-month follow-up, these changes were sustained,...
